HTB South

Conference reports

2015 Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle

Pipeline ART: tenofovir alafenamide (TAF)

Pipeline ART: maturation inhibitors and an attachment inhibitor

No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

“On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use

Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel

Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

Featured Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART

Featured Three drug ART best for preventing vertical transmission to infants: results from the PROMISE study

3 in 5 breastfeeding women with viral load >1,000 copies/mL are undiagnosed in Kenya, Malawi and South Africa

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Lopinavir/ritonavir in young children is superior to nevirapine after five years: results from long term follow up of IMPAACT P1060

Long-term safety and efficacy of tenofovir in children

UK case of HIV remission: ten years off-ART in patient with prior progression and treated during seroconversion

XXIV International HIV Drug Resistance Workshop
, 21-22 February 2015, Seattle, Washington

Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions

Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings

Drug resistance and integrase inhibitors: potential impact of HIV subtype

Drug resistance in children after PMTCT and early treatment

54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 5-9 
September 2014, Washington, DC

Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep

HIV persists in lung macrophages of people on suppressive ART

20th International AIDS Conference, 20-25 July 2014, Melbourne

Update on baseline STIs in UK oral PrEP study (PROUD)

High prevalence of COPD at baseline in START study sub-study

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Rosuvastatin may be partially effective in moderating residual immune activation on ART

Reasons for loss to follow up in the Malawi Option B+ programme

20th International AIDS Conference, 20-25 July 2014, Melbourne

The loss of friends and colleagues from flight MH 17

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

Pill A, Pill B: simplified second-line treatment for low-income countries

UNAIDS sets 90-90-90 target for 2020 to end AIDS by 2030

No difference in overall anaemia rate with reduced dose AZT

Open label oral PrEP at four doses a week: why zero infections does not equal 100% efficacy

Cure research at IAS 2014: TILDA measures the reservoir and romidepsin wakes it up

Publications launched at AIDS 2014

6th International Workshop on HIV Paediatrics, 18-19 July 2014, Melbourne

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents

Rationalising the paediatric antiretroviral formulary in Malawi

Time to first-line failure in the IeDEA cohort

Influence of early ART on antibody detection in children

8th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-Poor Settings (INTEREST), 5-6 May 2014, Lusaka, Zambia

Short-term safety of atazanavir/ritonavir-based second line treatment in Zambia

Pregnancy outcomes in Zambia

Uptake of ART is influenced by distance to the health facility in rural Zambia

Genotyping using dried blood spots in rural South African setting

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

ARV pipeline: doravirine, GSK-744 and BMS-068

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

Pharmacokinetic targets for efavirenz might be too high

Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

Lower newborn bone mineral content with maternal tenofovir use

Post navigation